Needless to say, the health care sector, especially
pharmaceuticals and biotech, have taken a rhetorical beating from politicians
looking to force the blame for high drug prices on some of the top companies.
While prices on some are indeed high, and perhaps should be lowered, the fact
of the matter is, it is incredibly expensive to get a new drug to approval and
the market. The selling of these stocks could give investors a great entry
point.
One of the firms we cover here at 24/7 Wall St. is UBS, and
it is cautiously positive on the overall health care sector. The analysts have
the sector rated moderate overweight, and the preferred segments are
pharmaceuticals and healthcare providers and services. We found four stocks in
the Most Preferred Pharmaceuticals list that pay top dividends.
Continue to read…
Source: 24/7 Wall St.